Kyu-pyo Kim

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial

Yong Sang Hong, Byung‐Ho Nam, Kyu-pyo Kim et al. · The Lancet Oncology · 2014 · 384 citations

Medicine, Oncology, Surgery +17

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

Yong Sang Hong, Sun Young Kim, Ji Sung Lee et al. · Journal of Clinical Oncology · 2019 · 167 citations

Medicine, Oncology, Surgery +17

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Ivana Yen, Jeeyun Lee, Yong Sang Hong et al. · Nature · 2021 · 135 citations · Full text

Medicine, Oncology, Pharmacology +14

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

Yong Sang Hong, Young Suk Park, Ho Yeong Lim et al. · The Lancet Oncology · 2012 · 132 citations

Medicine, Oncology, Chemotherapy +9

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group

Changhoon Yoo, Hyeon-Su Im, Kyu-pyo Kim et al. · Therapeutic Advances in Medical Oncology · 2019 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17